London, UK, 19 February 2010 - Ark Therapeutics Group plc (AKT: LSE) ("Ark" or "the Company"), announces today that it has signed a non-binding Preferred Supplier Memorandum with Merck Sharpe & Dohme Corp. for the production of gene-based medicines at Ark's cGMP licensed facility in Kuopio, Finland. The appointment as preferred manufacturing supplier is subject to the signing of a binding detailed manufacturing agreement.
Nigel Parker, CEO at Ark, commented; "Ark's cGMP manufacturing facility has been validated to both EU and US standards. We are able to provide a unique full manufacturing service and supply high level expertise and regulatory support documentation through our experiences with our own late stage adenoviral products. We look forward to progressing this initiative with Merck."
Last updated on: 27/08/2010
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.